Ash Stevens, Inc. (ASI), has received approval from the FDA for its facility in Riverview, MI for the manufacture of the API ixazomib, an oral proteasome inhibitor indicated in combination with leanlidomide and dexamethasone for the treatment of multiple myeloma.
 
“Ixazomib is a novel, orally active drug, giving hope to certain patients suffering from multiple myeloma,” said Dr. Stephen Munk, chief executive officer and president of Ash Stevens. “The rapid approval by FDA to manufacture this important drug validates our mission to use chemistry to improve the quality of life for people suffering from a variety of conditions. We are extremely proud to be manufacturing a second, novel API for Takeda.”
 
Ash Stevens provides global contract pharmaceutical chemical development and API (Active Pharmaceutical Ingredient) manufacturing services.